Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will participate in three upcoming investor conferences in September.

Conference Details:

Event: Citi 18th Annual BioPharma Conference
Details: Hosting investor meetings Thursday, September 7, 2023, in Boston, MA

Event: H.C. Wainwright 25th Annual Global Investment Conference
Details: Presenting in a fireside chat format on Tuesday, September 12, 2023, at 8:30 AM ET and hosting investor meetings in New York, NY

Event: Cantor Global Healthcare Conference
Details: Presenting in a fireside chat format on Thursday, September 28, 2023, at 9:45 AM ET and hosting investor meetings in New York, NY

To access webcasts of the H.C. Wainwright and Cantor presentations, please visit the “Events & Presentations” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/. The presentations will be webcast live and archived on the website for at least 30 days following the events.

ABOUT LONGBOARD PHARMACEUTICALS

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no detectable activity on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). LP352 is currently being evaluated in a Ph 1b/2a clinical trial (the PACIFIC Study) in participants with DEEs, with data expected around year-end 2023, as well as in additional supportive studies. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of multiple neurological diseases.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s participation in the upcoming conferences and Longboard’s clinical and preclinical programs and product candidates, ability to develop product candidates and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.